Updated on 2025/03/19

写真a

 
HAYAI Shunsaku
 
Organization
Nagoya University Hospital Respiratory Medicine Assistant professor of hospital
Title
Assistant professor of hospital

Degree 1

  1. 学士 ( 2011.3   名古屋大学 ) 

Research Interests 1

  1. 肺癌

Research Areas 1

  1. Life Science / Respiratory medicine  / lung cancer

Education 1

  1. Nagoya University

    2005.4 - 2011.3

Professional Memberships 3

  1. 日本呼吸器学会   専門医

  2. 日本臨床腫瘍学会   がん薬物療法専門医 指導医

  3. 日本内科学会   総合内科専門医

 

Papers 13

  1. Bronchial occlusion with endobronchial Watanabe spigots using a two-scope technique for massive haemoptysis Open Access

    Baba, T; Ito, T; Sato, Y; Hayai, S; Koyama, J; Nakamura, S; Tokuda, Y; Chen-Yoshikawa, TF; Ishii, M

    RESPIROLOGY CASE REPORTS   Vol. 12 ( 6 ) page: e01405   2024.6

     More details

    Language:English   Publisher:Respirology Case Reports  

    Massive haemoptysis is a life-threatening condition whose cause needs to be identified rapidly so that prompt interventions can ensue. Bronchial occlusion with endobronchial Watanabe spigots (EWSs) may be useful when endovascular treatment or surgery proves to be difficult. An 84-year-old woman developed massive haemoptysis during percutaneous mitral valve repair for refractory heart failure due to severe mitral regurgitation (MR). Interventional radiology (IVR) and surgery were contraindicated, and bronchial occlusion with EWSs was attempted to control bleeding. The bleeding was so persistent that it was difficult to secure the visual field without aspiration with a bronchoscope. Herein, we report a two-scope technique, also used in cryobiopsy of peripheral lung lesions, to control bleeding and perform bronchial occlusion with EWSs.

    DOI: 10.1002/rcr2.1405

    Web of Science

    Scopus

    PubMed

  2. Pneumocystis pneumonia in a patient with severe generalized pustular psoriasis treated with biologics

    Noguchi, H; Takeichi, T; Hayai, S; Yoshikawa, M; Muro, Y; Akiyama, M

    JOURNAL OF DERMATOLOGY   Vol. 51 ( 4 ) page: e112 - e114   2024.4

     More details

    Language:English   Publisher:Journal of Dermatology  

    DOI: 10.1111/1346-8138.17014

    Web of Science

    Scopus

    PubMed

  3. Metabolic barriers in non-small cell lung cancer with <i>LKB1</i> and/or <i>KEAP1</i> mutations for immunotherapeutic strategies Open Access

    Tanaka, I; Koyama, J; Itoigawa, H; Hayai, S; Morise, M

    FRONTIERS IN ONCOLOGY   Vol. 13   page: 1249237   2023.8

     More details

    Language:English   Publisher:Frontiers in Oncology  

    Currently, immune checkpoint inhibitors (ICIs) are widely considered the standard initial treatment for advanced non-small cell lung cancer (NSCLC) when there are no targetable driver oncogenic alternations. NSCLC tumors that have two alterations in tumor suppressor genes, such as liver kinase B1 (LKB1) and/or Kelch-like ECH-associated protein 1 (KEAP1), have been found to exhibit reduced responsiveness to these therapeutic strategies, as revealed by multiomics analyses identifying immunosuppressed phenotypes. Recent advancements in various biological approaches have gradually unveiled the molecular mechanisms underlying intrinsic reprogrammed metabolism in tumor cells, which contribute to the evasion of immune responses by the tumor. Notably, metabolic alterations in glycolysis and glutaminolysis have a significant impact on tumor aggressiveness and the remodeling of the tumor microenvironment. Since glucose and glutamine are essential for the proliferation and activation of effector T cells, heightened consumption of these nutrients by tumor cells results in immunosuppression and resistance to ICI therapies. This review provides a comprehensive summary of the clinical efficacies of current therapeutic strategies against NSCLC harboring LKB1 and/or KEAP1 mutations, along with the metabolic alterations in glycolysis and glutaminolysis observed in these cancer cells. Furthermore, ongoing trials targeting these metabolic alterations are discussed as potential approaches to overcome the extremely poor prognosis associated with this type of cancer.

    DOI: 10.3389/fonc.2023.1249237

    Open Access

    Web of Science

    Scopus

    PubMed

  4. Complications of lung cancer in the clinical course of interstitial lung disease

    Noguchi, Y; Takei, R; Hayai, S; Oi, H; Yamano, Y; Yokoyama, T; Matsuda, T; Kataoka, K; Kimura, T; Kondoh, Y

    EUROPEAN RESPIRATORY JOURNAL   Vol. 60   2022.9

  5. Amelanotic Malignant Melanoma with a <i>BRAF V600E</i> Mutation Mimicking Primary Lung Cancer Open Access

    Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Kim Deoksu, Shimoyama Yoshie, Hashimoto Naozumi

    Internal Medicine   Vol. 61 ( 5 ) page: 703 - 708   2022.3

     More details

    Language:English   Publisher:The Japanese Society of Internal Medicine  

    <p>Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a <i>BRAF V600E</i> mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with <i>BRAF V600E</i> mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression. </p>

    DOI: 10.2169/internalmedicine.6657-20

    Open Access

    Web of Science

    Scopus

    PubMed

    CiNii Research

▼display all

Presentations 7

  1. Combination therapy with cisplatin and inhibition stress granule formation in lung cancer cells

    Hayai, S; Suzuki, M; Shinjo, K; Kondo, Y

    CANCER SCIENCE  2023.2 

     More details

    Event date: 2023.2

    Language:Japanese  

  2. Complications of lung cancer in the clinical course of interstitial lung disease

    Noguchi, Y; Takei, R; Hayai, S; Oi, H; Yamano, Y; Yokoyama, T; Matsuda, T; Kataoka, K; Kimura, T; Kondoh, Y

    EUROPEAN RESPIRATORY JOURNAL  2022.9.4 

     More details

    Event date: 2022.9

    DOI: 10.1183/13993003.congress-2022.210

  3. Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation

    Tanaka, K; Inui, N; Asada, K; Abe, T; Hataji, O; Hayai, S; Ito, K; Imaizumi, K; Kimura, T; Kubo, A; Kunii, E; Murotani, K; Okuno, M; Oya, Y; Shindoh, J; Taniguchi, H; Tsuda, T; Yamaguchi, T; Hida, T; Suda, T

    ANNALS OF ONCOLOGY  2018.11 

     More details

    Event date: 2018.11

  4. Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC

    Ito, K; Murotani, K; Kubo, A; Kunii, E; Taniguchi, H; Shindo, J; Asada, K; Imaizumi, K; Tanaka, K; Inui, N; Okuno, M; Hataji, O; Hayai, S; Abe, T; Kimura, T; Tsuda, T; Yamaguchi, T; Oya, Y; Yoshida, T; Hida, T

    ANNALS OF ONCOLOGY  2018.10 

     More details

    Event date: 2018.10

  5. Lung Cancer in Patients with Interstitial Lung Disease: Clinical Characteristics and Impact on Survival International conference

    Hayai, S; Taniguchi, H; Kondoh, Y; Kimura, T; Kataoka, K; Matsuda, T; Yokoyama, T

    JOURNAL OF THORACIC ONCOLOGY  2017.11 

     More details

    Event date: 2017.11

    Presentation type:Oral presentation (general)  

    DOI: 10.1016/j.jtho.2017.09.1731

▼display all